Last reviewed 2026-05-14 · How we verify

Ibandronate (SB743830HD)

GlaxoSmithKline · FDA-approved active Small molecule

Ibandronate (SB743830HD) is a Bisphosphonate Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Osteoporosis in postmenopausal women, Bone metastases in breast cancer, Hypercalcemia of malignancy.

Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.

Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Osteoporosis in postmenopausal women, Bone metastases in breast cancer, Hypercalcemia of malignancy.

At a glance

Generic name	Ibandronate (SB743830HD)
Sponsor	GlaxoSmithKline
Drug class	Bisphosphonate
Target	Farnesyl pyrophosphate synthase; hydroxyapatite in bone
Modality	Small molecule
Therapeutic area	Bone metabolism / Osteoporosis
Phase	FDA-approved

Mechanism of action

Bisphosphonates like ibandronate are taken up by osteoclasts during bone resorption and inhibit the mevalonate pathway enzyme farnesyl pyrophosphate synthase, leading to osteoclast apoptosis and reduced bone turnover. This mechanism decreases bone resorption and increases bone mineral density, making it effective for conditions characterized by excessive bone loss.

Approved indications

Osteoporosis in postmenopausal women
Bone metastases in breast cancer
Hypercalcemia of malignancy

Common side effects

Musculoskeletal pain
Gastrointestinal upset (nausea, dyspepsia)
Headache
Osteonecrosis of the jaw (rare, with prolonged use)
Atypical fractures (rare)

Key clinical trials

Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ibandronate (SB743830HD) CI brief — competitive landscape report
Ibandronate (SB743830HD) updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about Ibandronate (SB743830HD)

What is Ibandronate (SB743830HD)?

Ibandronate (SB743830HD) is a Bisphosphonate drug developed by GlaxoSmithKline, indicated for Osteoporosis in postmenopausal women, Bone metastases in breast cancer, Hypercalcemia of malignancy.

How does Ibandronate (SB743830HD) work?

Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.

What is Ibandronate (SB743830HD) used for?

Ibandronate (SB743830HD) is indicated for Osteoporosis in postmenopausal women, Bone metastases in breast cancer, Hypercalcemia of malignancy.

Who makes Ibandronate (SB743830HD)?

Ibandronate (SB743830HD) is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Ibandronate (SB743830HD) in?

Ibandronate (SB743830HD) belongs to the Bisphosphonate class. See all Bisphosphonate drugs at /class/bisphosphonate.

What development phase is Ibandronate (SB743830HD) in?

Ibandronate (SB743830HD) is FDA-approved (marketed).

What are the side effects of Ibandronate (SB743830HD)?

Common side effects of Ibandronate (SB743830HD) include Musculoskeletal pain, Gastrointestinal upset (nausea, dyspepsia), Headache, Osteonecrosis of the jaw (rare, with prolonged use), Atypical fractures (rare).

What does Ibandronate (SB743830HD) target?

Ibandronate (SB743830HD) targets Farnesyl pyrophosphate synthase; hydroxyapatite in bone and is a Bisphosphonate.

Drug class: All Bisphosphonate drugs
Target: All drugs targeting Farnesyl pyrophosphate synthase; hydroxyapatite in bone
Manufacturer: GlaxoSmithKline — full pipeline
Therapeutic area: All drugs in Bone metabolism / Osteoporosis
Indication: Drugs for Osteoporosis in postmenopausal women
Indication: Drugs for Bone metastases in breast cancer
Indication: Drugs for Hypercalcemia of malignancy

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing